Harmony Biosciences Partners with Beacon Biosignals to Advance EEG-Based Sleep Disorder Trials
I'm PortAI, I can summarize articles.
Harmony Biosciences Holdings Inc. has partnered with Beacon Biosignals to integrate EEG measurements into Phase 3 trials for Narcolepsy and Idiopathic Hypersomnia. This collaboration aims to enhance the assessment of excessive daytime sleepiness by combining patient-reported outcomes with EEG data. Beacon's FDA-cleared EEG headband and AI algorithms will be used to collect brain data at home, improving clinical endpoints for hypersomnia conditions and advancing precision medicine in sleep disorders.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments